Скачать с ютуб New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope в хорошем качестве

New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope

An international collaboration between ITM Isotope Technologies Munich SE (ITM), Bruce Power and Isogen (a Kinectrics and Framatome company), announced a milestone marking the first instance lutetium-177, a short-lived medical isotope, has been produced in a commercial nuclear power reactor. Lutetium-177 is a medical isotope used in the treatment of various cancers, such as neuroendocrine tumors and prostate cancer. ITM will receive exclusive access to the irradiation service provided by the new Isotope Production System (IPS) for the production of lutetium-177, further expanding its capabilities of producing this high-quality isotope at a large scale for hospitals worldwide, global partners, and ITM’s own clinical pipeline of radiopharmaceuticals for hard-to-treat cancers. These isotopes were then sent to ITM in Germany for processing, using its proprietary manufacturing methodology and industrial scale production capacities yielding high-quality, pharmaceutical-grade no-carrier-added lutetium-177 (n.c.a. lutetium-177), which ITM provides to health care facilities around the world.